Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-400 vs standard of care in post-adjuvant ctDNA-positive colorectal cancer with no radiographic evidence of disease
jRCT2031250247Phase 2Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, randomised, open-label trial in colorectal cancer (CRC) comparing ABBV-400 monotherapy with Standard of care / active surveillance (2 arms). Primary endpoint: Disease-free survival (DFS). Started Jul 2025; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031250247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250247.